scholarly journals CelloSelect – A synthetic cellobiose metabolic pathway for selection of stable transgenic CHO cell lines

Author(s):  
Ana P. Teixeira ◽  
Pascal Stücheli ◽  
Simon Ausländer ◽  
David Ausländer ◽  
Pascal Schönenberger ◽  
...  
2019 ◽  
Vol 35 (4) ◽  
pp. 65-72
Author(s):  
V.I. Pavelko ◽  
I.A. Kirik ◽  
V.N. Bade ◽  
T.O. Malygina ◽  
R.A. Khamitov ◽  
...  

Growth and productive characteristics of monoclonal cell lines based on CHO cells and producing a therapeutic protein have been monitored using the robot Ambr Tap Biosystems, which permitted to identify the leading line. Twenty four clones producing a recombinant monoclonal antibody were studied under the close to industrial conditions in a fed-batch culturing mode. The ambr®15 cell culture workstation controls 24 disposable mini bioreactors, and offers parallel processing and evaluation of multiple (24) experiments in an automated bench-top system. The volumetric productivity of 24 clones determined by ELISA was 120-450 mg /L. A protocol was shown to select a leader among producing clones for further research. producing clones, mini bioreactor; Ambr Tap Biosystems, fed-batch, monoclonal antibodies, CHO cell culture


2021 ◽  
Vol 22 (10) ◽  
pp. 5218
Author(s):  
Tomu Kamijo ◽  
Takahiro Kaido ◽  
Masahiro Yoda ◽  
Shinpei Arai ◽  
Kazuyoshi Yamauchi ◽  
...  

We identified a novel heterozygous hypofibrinogenemia, γY278H (Hiroshima). To demonstrate the cause of reduced plasma fibrinogen levels (functional level: 1.12 g/L and antigenic level: 1.16 g/L), we established γY278H fibrinogen-producing Chinese hamster ovary (CHO) cells. An enzyme-linked immunosorbent assay demonstrated that synthesis of γY278H fibrinogen inside CHO cells and secretion into the culture media were not reduced. Then, we established an additional five variant fibrinogen-producing CHO cell lines (γL276P, γT277P, γT277R, γA279D, and γY280C) and conducted further investigations. We have already established 33 γ-module variant fibrinogen-producing CHO cell lines, including 6 cell lines in this study, but only the γY278H and γT277R cell lines showed disagreement, namely, recombinant fibrinogen production was not reduced but the patients’ plasma fibrinogen level was reduced. Finally, we performed fibrinogen degradation assays and demonstrated that the γY278H and γT277R fibrinogens were easily cleaved by plasmin whereas their polymerization in the presence of Ca2+ and “D:D” interaction was normal. In conclusion, our investigation suggested that patient γY278H showed hypofibrinogenemia because γY278H fibrinogen was secreted normally from the patient’s hepatocytes but then underwent accelerated degradation by plasmin in the circulation.


2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Laura Bryan ◽  
Michael Henry ◽  
Ronan M. Kelly ◽  
Christopher C. Frye ◽  
Matthew D. Osborne ◽  
...  

Abstract Background The ability to achieve high peak viable cell density earlier in CHO cell culture and maintain an extended cell viability throughout the production process is highly desirable to increase recombinant protein yields, reduce host cell impurities for downstream processing and reduce the cost of goods. In this study we implemented label-free LC-MS/MS proteomic profiling of IgG4 producing CHO cell lines throughout the duration of the cell culture to identify differentially expressed (DE) proteins and intracellular pathways associated with the high peak viable cell density (VCD) and extended culture VCD phenotypes. Results We identified key pathways in DNA replication, mitotic cell cycle and evasion of p53 mediated apoptosis in high peak VCD clonally derived cell lines (CDCLs). ER to Golgi vesicle mediated transport was found to be highly expressed in extended culture VCD CDCLs while networks involving endocytosis and oxidative stress response were significantly downregulated. Conclusion This investigation highlights key pathways for targeted engineering to generate desirable CHO cell phenotypes for biotherapeutic production.


1988 ◽  
Vol 38 (4) ◽  
pp. 269-278 ◽  
Author(s):  
M. van Heuvel ◽  
M. Govaert-Siemerink ◽  
I. J. Bosveld ◽  
E. G. Zwarthoff ◽  
J. Trapman

Author(s):  
M. Kruszewski ◽  
H. Kruszewska ◽  
H. Inaba ◽  
P. Jeggo ◽  
I. Szumiel

BioTechniques ◽  
2018 ◽  
Vol 65 (1) ◽  
pp. 41-46 ◽  
Author(s):  
DC Soler ◽  
AE Young ◽  
A Vahedi-Faridi ◽  
TS McCormick

1999 ◽  
Vol 24 (1) ◽  
pp. 13-16 ◽  
Author(s):  
Mamoru HORIKOSHI ◽  
Takashi HIROOKA
Keyword(s):  

2010 ◽  
Vol 26 (5) ◽  
pp. 1446-1454 ◽  
Author(s):  
Alison J. Porter ◽  
Alan J. Dickson ◽  
Andrew J. Racher
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document